Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Hospital Authority, Hong Kong The University of Hong Kong |
---|---|
Information provided by: | Hospital Authority, Hong Kong |
ClinicalTrials.gov Identifier: | NCT00517270 |
Non-cardiac chest pain accounts for 2-5% of all emergency presentations. In the United States, it has been estimated approximately that US$8 billion was spent annually for the initial care of patients suspected to have an acute coronary syndrome, but who were subsequently found not to have coronary artery disease (1). The most common cause of non-cardiac chest pain is gastro-oesophageal reflux disease (2). Two randomized, double-blind, placebo-controlled trials on the use of omeprazole versus placebo for the treatment of NCCP have been published in the western population and reported an efficacy of 62% to 80% (3,4). High-dose omeprazole was used in the previous trials (3,4). Recently, it has been shown that rabeprazole, which is a newly developed benzimidazole proton pump inhibitor, is a more potent and rapid inhibitor of H+,K+-ATPase and acid secretion than omeprazole, lansoprazole and pantoprazole (5,6). Whether the above findings applied to Chinese population is unknown. Thus we would like to propose a randomized double-blind placebo-controlled trial to study the effects of high-dose proton pump inhibitor for the treatment of non-cardiac chest pain in Chinese population. The aim of this study is to evaluate the efficacy of high-dose proton pump inhibitor for the treatment of gastro-oesophageal reflux related non-cardiac chest pain.
Condition | Intervention |
---|---|
Chest Pain |
Drug: Rabeprazole 20mg twice daily |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | High-Dose Proton Pump Inhibitor for the Treatment of Gastro-Oesophageal Reflux Related Non-Cardiac Chest Pain - a Randomized Double-Blind Placebo-Controlled Study. |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ting Kin Cheung, Dr | (852) 2855 3989 | cheungtk@hkucc.hku.hk |
China | |
Queen Mary Hospital | Recruiting |
Hong Kong, China | |
Sub-Investigator: Benjamin CY Wong, Dr |
Principal Investigator: | Ting Kin Cheung, Dr | Department of Medicine, The University of Hong Kong |
Study ID Numbers: | EC1932-02, HARECCTR0500032 |
Study First Received: | August 15, 2007 |
Last Updated: | December 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00517270 |
Health Authority: | Hong Kong: Ethics Committee |
Non-cardiac chest pain |
Deglutition Disorders Esophageal Motility Disorders Signs and Symptoms Digestive System Diseases Esophageal disorder Gastrointestinal Diseases |
Pain Esophageal Diseases Gastroesophageal Reflux Rabeprazole Chest Pain |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Ulcer Agents |
Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |